SANGAMO THERAPEUTICS, INC

Analysis for Ticker: SGMO

Sangamo Therapeutics Inc tries to fix broken genes with zinc finger technology, focusing on brain diseases and rare disorders like Fabry disease. But the science is just one mask for a 1,6$ billion accumulated deficit and one math equation that is eating itself alive. During 2025, they lost 122,9$ million while their bank account dwindled to just 20,9$ million. Imagine one child with one piggy bank that has one giant hole in the bottom; every time they get one coin, it falls out, so they have to keep asking their friends for more coins while promising to give away pieces of their toys. The disaster is that the company is printing so many new pieces of ownership that the pieces held by everyone else are losing their value faster than the company can find new coins. The mechanism of this decay accelerated during 01/2025 when partners like Biogen, Novartis, and Kite walked away, followed by Pfizer ending a major contract in 04/2025. By 30/04/2025, the stock market noticed the cash was disappearing and the share price fell below 1,00$ for thirty straight days. This triggered one warning that the company would be kicked off the exchange. Management bought time by getting one extension until 27/04/2026, but the fundamental math did not change.